NasdaqCM - Nasdaq Real Time Price USD

NRx Pharmaceuticals, Inc. (NRXP)

3.6700

+0.4000

+(12.23%)

At close: June 9 at 4:00:01 PM EDT

3.7300

+0.06

+(1.63%)

Pre-Market: 5:34:12 AM EDT

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...

NewMediaWire 3 days ago

NRXP
+12.23%

NRXPW
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 5, 2025 /New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage ...

ACCESS Newswire 4 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviate...

NewMediaWire 4 days ago

NRXP
+12.23%

NRXPW
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management.

PR Newswire 4 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 28, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...

NewMediaWire 12 days ago

NRXP
+12.23%

NRXPW
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and its subsidiary, HOPE Therapeutics, Inc., are making a major move in mental health care with the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California. Announced today, the definitive agreement marks a strategic expansion for NRXP, positioning Kadima as the clinical model for HOPE’s planned network of interventional psychiatry clinics […]

Insider Monkey 13 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 27, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...

NewMediaWire 13 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 21, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...

NewMediaWire 19 days ago

NRXP
+12.23%

NRXPW
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will be presenting a Company update at the upcoming Wall Street Conference, taking place on May 21, 2025 in Palm Beach, FL. NRx is one of six companies invited to present.

PR Newswire 19 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 20, 2025 (NEWMEDIAWIRE) - Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is ...

NewMediaWire 20 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 16, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 ne...

NewMediaWire 24 days ago

NRXP
+12.23%

NRXPW
NRX Pharmaceuticals Inc (NRXP) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

NRX Pharmaceuticals Inc (NRXP) reports reduced losses and operational expenses while advancing key drug candidates towards FDA approval.

GuruFocus.com 25 days ago

NRXP
+12.23%

NRXPW
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update.

PR Newswire 25 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 15, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to ...

NewMediaWire 25 days ago

NRXP
+12.23%

NRXPW
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa.

PR Newswire 25 days ago

NRXP
+12.23%

NRXPW
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 13, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wh...

NewMediaWire 27 days ago

NRXP
+12.23%

NRXPW
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research in

PR Newswire 27 days ago

NRXP
+12.23%

NRXPW
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.

PR Newswire 28 days ago

NRXP
+12.23%

NRXPW
Psychedelic: Compass, GH Research, MindMed report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin

TipRanks last month

CYBN

GHRS

CMPS
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage bioph...

NewMediaWire last month

NRXP
+12.23%

NRXPW

Performance Overview

Return	NRXP	S&P 500 (^GSPC)
YTD	+66.82%	+2.11%
1-Year	+14.33%	+12.32%
3-Year	-36.61%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NRx Pharmaceuticals, Inc. (NRXP)

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

NRX Pharmaceuticals Inc (NRXP) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation

Performance Overview